MDGEF Stock - Medigene AG
Unlock GoAI Insights for MDGEF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $6.03M | $31.25M | $10.46M | $8.00M | $10.51M |
| Gross Profit | $4.39M | $7.41M | $5.67M | $238,000 | $7.81M |
| Gross Margin | 72.8% | 23.7% | 54.2% | 3.0% | 74.3% |
| Operating Income | $-16,149,000 | $-9,120,000 | $-10,511,000 | $-27,198,000 | $-20,282,000 |
| Net Income | $-16,177,000 | $-8,330,000 | $-9,983,000 | $-28,875,000 | $-19,962,000 |
| Net Margin | -268.1% | -26.7% | -95.4% | -360.8% | -189.9% |
| EPS | $-1.32 | $-0.64 | $-0.77 | $-2.23 | $-1.54 |
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Visit WebsiteEarnings History & Surprises
MDGEFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 31, 2025 | — | — | — | — |
Q2 2025 | Apr 28, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Oct 24, 2024 | — | — | — | — |
Q3 2024 | Aug 15, 2024 | $-0.60 | $-0.16 | +73.1% | ✓ BEAT |
Q2 2024 | Apr 26, 2024 | — | — | — | — |
Q1 2024 | Mar 28, 2024 | $-1.07 | $-0.21 | +80.7% | ✓ BEAT |
Q1 2024 | Jan 8, 2024 | — | $-0.20 | — | — |
Q3 2023 | Aug 17, 2023 | — | $-0.17 | — | — |
Q2 2023 | Jun 30, 2023 | $-0.79 | $-0.18 | +77.1% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | — | $-0.49 | — | — |
Q4 2022 | Nov 2, 2022 | — | $-0.44 | — | — |
Q3 2022 | Aug 3, 2022 | — | $-0.10 | — | — |
Q2 2022 | May 4, 2022 | — | $0.31 | — | — |
Q1 2022 | Mar 23, 2022 | — | $-0.19 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-0.10 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-0.26 | — | — |
Q2 2021 | Apr 5, 2021 | — | $-0.14 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.77 | — | — |
Q4 2020 | Nov 12, 2020 | — | $-0.39 | — | — |
Latest News
Frequently Asked Questions about MDGEF
What is MDGEF's current stock price?
What is the analyst price target for MDGEF?
What sector is Medigene AG in?
What is MDGEF's market cap?
Does MDGEF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MDGEF for comparison